Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 1 Aug 2009

Zhou Yang, Hou Ying-yong, Tan Yun-shan, Lu Shao-hua, Hou Jun, Liu Jing-lei, Qin Jing, Shen Kun-tang, Sun Yi-hong

Abstract excerpt

OBJECTIVE: To investigate the mechanism of imatinib mesylate (IM) induced-resistance in the patients with gastrointestinal stromal tumors (GISTs) and treated with imatinib. METHODS: Eight patients with GIST treated with IM developed secondary IM resistance. A total of 16 tumor samples (pre-IM therapy) and 11 tumor samples (post-IM treatment) were available. Exon 9, 11, 13, and 17 of c-kit gene as well as exon 12...

Topics

Join the communities discussing this publication.

Benzamides
Gastrointestinal Stromal Tumors
Imatinib Mesylate
Neoplasm Recurrence, Local
Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins c-kit

Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 20021947

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].PMID 20021947Read ↗

[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

[Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].Semantic proximity Read ↗

[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].Semantic proximity Read ↗

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

[Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].Semantic proximity Read ↗

CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?Semantic proximity Read ↗

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Semantic proximity Read ↗

[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].Semantic proximity Read ↗

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

[The importance of mutational status in prognosis and therapy of GIST].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.